MICROWAVE ABLATION VS SURGERY
WHEN ABLATION IS THE RIGHT CHOICE
The question is not whether ablation or surgery is better โ both are essential tools. The question is which is better for this specific patient, this specific tumour, in this clinical context. This page provides the honest answer.
analyticsAt a Glance
- check_circleFor small well-located tumours in cirrhotic or high-risk patients, ablation outcomes match surgery with far less morbidity
- check_circleFor larger or surgically accessible tumours in fit patients, surgery has stronger evidence and remains the standard
- check_circleOrgan preservation is ablation's key advantage โ critical for liver, kidney, and lung function
- check_circleThe decision requires multi-disciplinary team review โ not a choice patients should make unilaterally
The Right Framework: Complementary, Not Competing
A common mistake is framing the ablation vs surgery decision as a competition between a "new" and "old" treatment. This is wrong. Surgery and ablation have different strengths and suit different patients. The right question for every patient is: which treatment provides the best balance of cancer control and safety for this specific situation?
โSurgery is not better than ablation. Ablation is not better than surgery. Each is better in certain situations. The multi-disciplinary team exists to match treatment to situation.โ
When Surgery Is the Standard
Surgery has the longest track record, the most phase III evidence, and provides definitive pathological confirmation of treatment. For patients who are surgically fit and have resectable disease, surgery remains the standard of care in most tumour types โ hepatic resection for HCC and CRC mets, lobectomy for lung cancer, nephrectomy for larger kidney tumours. Ablation does not replace surgery in these patients.
When Ablation Changes the Equation
Ablation becomes the preferred option when surgery carries disproportionate risk โ cirrhotic liver that cannot tolerate resection, cardiac or pulmonary comorbidities that increase surgical mortality, prior organ surgery leaving limited functional reserve, or patient age and frailty making recovery unlikely. In these patients, ablation provides comparable cancer control with a fraction of the procedural risk.
Decision Guide by Organ and Tumour Type
How the ablation vs surgery decision is typically framed for each major cancer indication.
| Cancer / Organ | When Surgery Is Preferred | When MWA Is Preferred | Key Evidence |
|---|---|---|---|
| HCC (Liver Primary) | Resectable tumour โค5 cm; Child-Pugh A; adequate liver reserve; no portal hypertension | Cirrhosis limiting resection; tumour โค3 cm in cirrhotic liver; prior hepatic surgery; bridge to transplant | Multiple RCTs; BCLC guidelines place both as curative options for stage 0/A |
| CRC Liver Metastases | Resectable lesions with adequate margins and sufficient remaining liver | Unresectable due to location, multifocal distribution, or prior surgery; salvage ablation after resection | CLOCC phase III (ablation+chemo vs chemo alone) |
| NSCLC (Lung) | Stage IโII surgically fit patient; adequate lung function for lobectomy | Medically inoperable due to COPD, cardiac, or other comorbidity; patient preference after counselling | Multiple MWA series; compared to SBRT (both non-surgical options) |
| Renal Cell Carcinoma | Fit patient with T1bโT2 tumour; younger patient; high surgical preference | T1a <4 cm; single kidney or bilateral disease; CKD; comorbidities elevating surgical risk; elderly | AUA/EAU guidelines: ablation acceptable alternative for T1a |
| Thyroid (Benign Nodule) | Large nodule >6 cm; compressing airway; confirmed malignancy | Symptomatic benign nodule; patient avoidance of surgery/scar; normal thyroid function desirable | Korean guidelines; ETA guidelines support ablation for benign nodules |
| Pulmonary Metastases | Fit patient with accessible single/few mets; surgical wedge resection feasible | Multiple lesions; bilateral disease; limited pulmonary reserve; repeated sessions needed over time | Multiple institutional series; no head-to-head RCT |
Specific Scenarios Where Ablation Is Clearly the Better Choice
These clinical scenarios represent situations where the multi-disciplinary team consensus strongly favours ablation over surgery, often regardless of tumour size within ablation range.
Advanced Cirrhosis (Child-Pugh B)
In cirrhotic patients with limited liver reserve, surgical resection risks post-operative liver failure โ the leading cause of mortality after hepatic surgery in cirrhotic patients. MWA spares healthy liver tissue entirely. For Child-Pugh B patients with small HCC, ablation is typically the only curative-intent local treatment option; surgery carries prohibitive mortality.
Single Kidney or Bilateral Renal Tumours
Removing kidney tissue in a patient with one functioning kidney risks dialysis dependency. MWA's nephron-sparing precision โ destroying only the tumour and a small margin โ is unmatched by any surgical approach. Even for patients who could anatomically tolerate partial nephrectomy, renal MWA is strongly favoured when functional preservation is the priority.
Severe COPD and Inoperable Lung Cancer
Lobectomy for stage I lung cancer requires adequate FEV1 and DLCO. Patients with FEV1 <50% predicted are not lobectomy candidates. For these patients, MWA (or SBRT) offers curative-intent treatment without removing functioning lung tissue. MWA's recovery is substantially faster and less demanding than any lung surgery.
Post-Hepatic Surgery Recurrence
Patients who have already had liver surgery and developed new lesions may have insufficient remaining liver for further resection. Repeat hepatic surgery also carries substantially higher risk than initial surgery due to adhesions and altered anatomy. MWA can address new lesions with minimal additional liver tissue loss, preserving functional reserve for ongoing treatment.
Advanced Age with Multiple Comorbidities
For elderly patients (typically >75) with multiple comorbidities, general anaesthesia and surgical recovery carry real risks of cardiac events, delirium, and prolonged rehabilitation. MWA under conscious sedation provides equivalent local tumour control with a substantially more favourable risk profile in frail patients.
MWA vs Surgery: Direct Comparison
A practical head-to-head comparison of the two treatment approaches across clinically relevant dimensions.
Microwave Ablation
- Minimally InvasiveNeedle-based access; no incision; preserves all organ tissue outside the tumour and margin.
- Same-Day or OvernightMost patients discharged within 24 hours; return to normal activities in days.
- No General Anaesthesia RequiredConscious sedation for most cases; lower cardiovascular and anaesthetic risk.
- Organ Function PreservationCritical advantage in liver, kidney, and lung where functional reserve matters.
- RepeatableNew lesions can be treated with repeat sessions without cumulative organ damage.
- Lower Procedural CostSubstantially lower procedure cost than open or laparoscopic surgery.
Surgical Resection
- Gold Standard for Resectable DiseaseLongest track record, most phase III evidence, established survival data across tumour types.
- Definitive PathologyFull histological assessment including margins, lymph nodes, and grade โ not available with ablation.
- Better for Larger TumoursNo size ceiling โ surgery can remove tumours of any size that are technically accessible.
- Lymph Node AssessmentRegional lymph node sampling at surgery provides staging information that ablation cannot.
- More Complete Tumour RemovalPathological confirmation of negative margins provides certainty not available from imaging after ablation.
- Strongest Guideline SupportNCCN, ESMO, EASL, EAU guidelines consistently position surgery as the first-line curative option where feasible.
Related Treatments & Resources
Explore the full microwave ablation knowledge base.
- What Is Microwave Ablation? A Patient Introduction
- Microwave Ablation for Liver Cancer (HCC): Evidence and Outcomes
- Microwave Ablation for Kidney Cancer (RCC)
- Microwave Ablation for Lung Cancer: NSCLC and Pulmonary Metastases
- Questions to Ask Before Microwave Ablation
- Microwave Ablation โ Full Treatment Page
Frequently Asked Questions
Common questions about choosing between ablation and surgery.
About the Decision
My surgeon says I need surgery โ should I get a second opinion on ablation?
Yes, asking for an interventional radiology opinion is entirely reasonable if you have concerns about surgical risk, recovery, or organ preservation. Many patients are initially referred to surgeons and never see an interventional radiologist. A multi-disciplinary team discussion that includes both a hepatobiliary surgeon and an interventional radiologist provides the most balanced assessment. CancerFax can arrange case review by both disciplines.
Can I have surgery later if ablation fails?
Yes, in most cases. Prior MWA does not preclude subsequent surgery in most clinical scenarios. For liver tumours, local recurrence after ablation can typically still be surgically resected if anatomically feasible. For kidney tumours, prior ablation does not prevent subsequent partial or radical nephrectomy. Keeping surgery as a "backup option" is a reasonable approach when ablation is chosen first for high-risk surgical patients.
My tumour is 4 cm โ is that too large for ablation?
A 4 cm tumour is at the upper edge of standard single-antenna MWA and the lower end of the size range where multi-antenna technique or TACE+MWA combination are often used. For a 4 cm liver tumour in a non-surgical patient, experienced centres can achieve complete ablation with appropriate multi-antenna or combination protocols. Whether ablation or surgery is right for a specific 4 cm tumour depends on location, organ function, and patient factors โ not size alone.
Process and Access
How does a multi-disciplinary team help me decide?
An MDT review brings together the surgeon, interventional radiologist, medical oncologist, and often a hepatologist or pulmonologist to review your specific case โ imaging, organ function, tumour characteristics, comorbidities, and treatment goals. Each specialist advocates for their modality where appropriate, and the team reaches a consensus recommendation. This prevents single-specialty bias in either direction. Request MDT discussion explicitly if it is not automatically offered.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Not Sure If Ablation or Surgery Is Right for You?
Upload your medical records and our multi-disciplinary oncology team will review your case โ providing an honest assessment of whether ablation or surgery is the more appropriate approach for your specific tumour and clinical situation.
For informational purposes only. Ablation vs surgery decisions require multi-disciplinary team evaluation with your treating specialists.